January Has Been the Best Month Ever for Biotech in Spain

February 7, 2018 - 2 minutes

Biotech in Spain has kicked off 2018 setting a record for the number of acquisitions and fundraisings and their total value combined. 

Early in January, the Japanese big pharma Takeda announced its intention to acquire TiGenix for €520M. The cell therapy biotech was born in 2011 as a merger of Belgian TiGenix and Spanish Cellerix, and part of the proceeds will go to Ysios Capital, a leading Spanish biotech investor based in Barcelona.

Soon followed the news fo the acquisition of STAT-Dx, a diagnostics biotech based in Barcelona that also counts with investment from Ysios. Qiagen has offered up to €153M to get hold of its technology.

On top of these big deals, the online investment platform Capital Cell has raised €4.7M that will go into Spanish biotechs, and service provider BDI Biotechnology has closed a €3.9M round.

The year seems off to a good start for European biotech, with the acquisition of Belgian Ablynx, one of the largest biotechs in Europe, for €3.9Bn topping it off at the end of the month. The record for Spanish biotech is definitely a sign that, as its leaders say, the country’s biotech ecosystem is getting up to speed with other countries like the UK, Germany or France.

Picture via NASA Images

Content continues below

Related Content

You might also be interested in the following: